Format

Send to

Choose Destination
HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228.

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

Author information

1
Orlando Immunology Center, Orlando, Florida, USA.

Erratum in

  • HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233.

Abstract

We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00369941.

PMID:
22849964
DOI:
10.1310/hct1304-228
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center